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A: Demographic and Pathogenetic Features 








Symptoms and signs 
Chest radiographic features 
Electrocardiographic features 
Pulmonary function tests, arterial 
blood gas and haematocrit 
measurements 
Radionuclide lung scans 
Pulmonary angiography and lower 
limb venography 
Haemodynamic data 
C: Exercise studies 
D: Response to vasodilator therapy 





























The diagnosis of primary pulmonary hyperten
sion 





presents several problems. These are of pa
rticular relevance 
when selection of patients for, and timin
g of heart-lung 
transplantation is being considered. 
I performed a retrospective study on patie
nts with PPH and 
chronic large vessel thromboembolic pulmo
nary hypertension 
(TPH) seen at Groote Schuur Hospital between 19
57 and 1985 
in an attempt to: 
1. Establish the diagnostic and prognostic
 value of clinical 
features, lung function tests, cardiac ca
theterisation, 
isotope lung scans and, 
therapy; 
in the PPH group, response to 
2. Review our experience of the effects of 
treatment with 
vasodilators and oral anticoagulants, and 
the results of 
heart and lung transplantation in the PPH g
roup; 
3. Attempt to identify features which cou
ld be used to 
predict prognosis in PPH; and thereby 
4. Define criteria for selecting PPH patients 
whose 




Where possible patients were recalled for 
assessment. 38 
patients with PPH and 16 with TPH were studi
ed. All patients 
with total lung capacity, forced vital ca
pacity or forced 
expiratory volume in 1 second to forced vita
l capacity ratio 
less than 2/3 predicted were excluded. 
The PPH patients were younger than those
 with TPH. A 
preponderance of females was present 
in both groups. 
Raynaud's phenomenon occurred significantly
 more frequently 
in the PPH group. The higher prevale
nce of a right 
ventricular fourth heart sound in this gro
up could not be 
explained and may have been a chance
 occurrence. 
Electrocardiographic evidence of right ax
is deviation and 
right ventricular hypertrophy occurred more 
frequently. Mean 
total lung capacity was considerably belo
w predicted and 
significantly lower than in the TPH group. 
Mean pulmonary 
the PPH group. 
artery pressure was significantly higher in
 
A gr~ater degree of ventilation/perfusipn 
mismatching in the TPH patients was s
uggested by the 
significantly lower mean systemic arterial 
oxygen saturation. 
Normal or low probability radionuclide lung
 scans were found 
in all cases with PPH, while all TPH p
atients had high 
probability scans. 
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Staqe I exercise studies performed in 4 PPB patients at 
diaqnosis showed significant limitation of effort tolerance, 
but there was no correlation between performance and several 
resting haemodynamic variables. 
Retrospective 
identified PPH 
analysis failed to 





therapy. Long term vasodilator administration appeared to be 
effective in only 2 of 6 patients. 
54% survived 4Ci! 
Electrocardiographic 
months from the onset of 
evidence of right 
symptoms. 
ventricular 
hypertrophy occurred less frequently in the long survival 
qroup (40 months or more from diaqnosis). This group also 
had a lower mean pulmonary artery pressure than the short 
survival group (12 months or less from diaqnosis). Neither 
mean pulmonary artery pressure, 





systemic arterial oxygen saturation nor systemic vascular 
resistance were directly related to survival in the short and 
long survival groups. No correlation was found between the 
pulmonary artery pressure and the severity of the 
histological changes. 
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The prognosis of PPH patients treated conservatively appears 
to be better than originally reported. Heart-lung 
transplantation should be considered for patients with severe 




Primary pulmonary hypertension (PPH) was first described as a 
pathological entity in the late nineteenth and early 
twentieth century. (
72 , 96 ) In 1935 Brenner correlated the 
clinical picture with the histopathological findings. (
7 ) The 
first clinical description including catheterization data was 
published in 1951 by Dresdale and his coworkers. (
29
> In 1970 
Wagenvoort and Wagenvoort defined criteria for the various 
h . t th 1 . 1 f d · h · (
122 > 1s opa o og1ca patterns oun 1n t ese patients. A 
World Health Organization meeting in 1973 
information regarding the pathogenesis, 
reviewed the 
pathophysiology, 
clinical patterns, epidemiology, morphology and nomenclature 
of this condition!
42 ) The areas for further study which were 
identified at this meeting have guided much of the subsequent 
research in this field. 
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Nomenclature 
The term "primary pulmonary hypertension" has been used in 
two quite separate ways: it has been used by the clinician 
to indicate the presence of an elevated pulmonary arterial 
pressure in the absence of a discernible cause whereas the 
patholooist has used it to imply a distinct histological 
pattern characterized by concentric intimal fibrosis, 
necrotizing arteritis, plexiform lesions and other associated 
features with no pathological evidence as to the cause of 
these changes. The WHO report suggested that the term 
"plexogenic pulmonary arte~iopathy" be used to describe this 
specific histological entity and that the term "primary 
pulmonary hypertension" be restricted to usage in a clinical 
sense to imply pulmonary hypertension for which clinical 
investigations fail to reveal a cause. This clinical 
category includes 3 distinct histopathological patterns: 
(a) plexoqenic pulmonary arteriopathy; <
21 ,1 22) 
(b) pulmonary veno-occlusive disease (PVOD) 
is widespread occlusion of pulmonary 
(1~9 llR) 
in which there 
veins and 
venules ' ; or 
(c) recurrent pulmonary microthromboembolism(
3l,l 22 ). 
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Although it is now possible in some instances to recognize 
PVOD and TPH during life there are other cases where even 
after full clinical investigation it is still impossible to 
differentiate the condition from plexogenic pulmonary 
arteriopathy. Only these cases would be included in the 
category of primary pulmonary hypertension. 
0 
Aims 
The aims of the present study were: 
(1) To analyze the features of patients seen at Groote 
Schuur Hospital with primary pulmonary hypertension and 
to compare them with those with chronic large vessel 
thromboembolic pulmonary hypertension; 
(2) To evaluate the prognosis of the patients in these two 
groups; 
(3) To assess the effect of treatment with anticoagulants, 
vasodilators and heart-lung transplantation in the 
primary pulmonary hypertension group; and 
(4) To attempt to identify factors predictive of prognosis 
in primary pulmonary hypertension and thereby to define 




We define primary pulmonary hypertension clinically as 
pulmonary hypertension (mean pulmonary artery pressure 25 
mmHg or greater at rest with pulmonary capillary wedge or 
left atrial pressure 15 mmHg or less) with no clinical, 
-cardiac catheterization or pulmonary angioqraphic evidence of 
congenital heart disease, pulmonary artery thromboembolic 
lesions, pulmonary veno-occlusive disease or significant 
disturbances in ventilation (total lung capacity, forced 
vital capacity or ratio of FEV1to 
FVC less than 
2/3 
predicted). This definition excludes such diseases as mitral 
stenos is, left atrial tumours, clinically demonstrable 
pulmonary venous disease, left ventricular dysfunction or 
severe restrictive or obstructive lung disease. Significant 
restriction of pulmonary volumes has been reported in 
patients with primary or chronic thromboembolic pulmonary 
hypertension 
disease. (9 , 47 ) 
with no evidence of interstitial lung 
I nevertheless chose to exclude patients with 
significant abnormalities in lung function to ensure that no 
patient with pulmonary hypertension aggravated by coexisting 
lung disease was included in this study. 
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VII: METHODS 
Th i rty-eight patients with primary pulmonary hypertension who 
were seen between 1957 and 1985 at Groote Schuur Hospital 
were reviewed. Sixteen patients with chronic pulmonary 
hypertension due to thromboembolism involving large and 
medium sized pulmonary arteries who presented during the same 
period were also reviewed in order to enable comparison of 
the clinical features at presentation and subsequent course 
of the disease process in the two groups. Patients were 
identified by means of the hospital computer retrieval system 
and the records of the cardiac and respiratory clinics. All 
those who met the defined diagnostic criteria were included. 
These patient groups necessarily included patients 
investigated to differing degrees as certain investigations 
only became available durinq the later years of the study. 
Clinical features at the time of diagnosis were obtained from 
~he patients' clinical notes. The onset of the disease was 
defined as the time of the first symptom. Chest radiographs, 
radioisotope lung scans and pulmonary histology were reviewed 
where possible. Failing this, the formal reports issued at 
the time of investigation were used. Haemodynamic and 
pulmonary angiographic data were obtained from the original 
reports. In those patients in whom pulmonary function tests 
were performed, forced vital capacity (FVC), total lung 
capacity (TLC) by helium dilution method, single breath gas 
transfer for carbon monoxide (~LCO SB) and KCO (gas transfer 
per litre luna volume) were measured using standard equipment 
Paae 13 
and methods. ~he results were corrected to BTPS and 
exp ressed as a percentaqe of predicted value for sex, age and 
h . ht (20,40,1~8) e1g • Forced expiratory volume in 1 second 
(FEV
1
) was expressed as a percentage of FVC. 
Radionuclide perfusion lung scans were performed on 19 
patients using 4 mCi of 99m-technetium labelled 
macroaggregated human albumin imaged in 4 views with a gamma 
camera. Where these showed abnormalities 2 further views in 
the right and left lateral positions were done. Ventilation 
scans were performed in which an Alm-krypton and air mixture 
was breathed at tidal volumes. Where possible the scans were 
reviewed. In other cases we used the report issued at the 
time of the investigation. Abnormal scans were interpreted 
as showing a high or low probability of pulmonary embolism. 
A high probability (HP) scan showed multiple lobar or 
segmental perfusion defects without ventilation abnormality 
' 
while multiple subsegmental (patchy) perfusion defects were 
interpreted as a low probability (LP) scan. 
Pulmonary haemodynamics and acute response to vasodilator 
therapy were evaluated either during a full study in the 
cardiac catheterization laboratory or by means of right heart 
catheterization in the respiratory intensive care unit. A 
change greater than 10% of the resting baseline haemodynamic 
parameters was considered significant. 
Pulmonary anqiography was performed by members of the Cardiac 
Clinic, Groote Schuur Hospital and their reports form the 
basis of our evaluation. 
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Complete or partial obstruction of 
a main or several lobar pulmonary arteries was considered 
ediagnostic of pulmonary embolic disease. The absence of 
large vessel obstruction or strictures and the occlusion of 
small peripheral vessels was taken to indicate a diagnosis of 
PPH. 
Stage 1 maximal exercise testing was performed on five 
patients usinq the method of Jones and Campbell.< 53 ) Of the 
four patients who had been tested at the time of diagnosis 
three were recalled for re-testing together with a fifth 
patient who had not been tested at the time of her initial 
diagnosis. 
Follow up information was obtained from the clinical notes 
and, where they were incomplete, attempts were made to 
contact the patients themselves, their families, or their 
attending doctors by letter, telephone or personal visit. 
Four PPH patients {the only survivors resident in Cape Town) 
were recalled for clinical re-evaluation, chest X-ray, 
pulmonary function tests and stage 1 exercise studies. Only 
those patients who had adequate follow up information {to 
death or for forty months from the onset of symptoms) 
included in the analysis of survival. 
were 
All patients who had undergone cardiac catheterization and 
who had been adequately followed up {to death or for 40 
months or more from the time of catheterization) were 
categorized into two groups: Group 1 (7 patients) who died 
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within 12 months of catheterization and Group 2 (7 patients) 
who survived for 4A months or longer after catheterization. 
The characteristic features of the two groups were evaluated 
and compared. 
The histological features of lung biopsy or autopsy specimens 
were reviewed where possible. 
Differences between groups were assessed by means of Mann-
Whitney U test and Fisher's exact test. The survival time in 
the short and long survival 
to measured haemodynamic 
groups was examined in relation 
data at the time of initial 
assessment by means of Spearman's rank correlation 
coefficient. Statistical significance was taken as p<0.~5. 
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VIII: RESULTS 
VIII A: Demographic and Pathogenetic Features 
Table VIII A(i): Demographic data of patients studied. 
Number of patients 
Age (years) 
Symptom duration before 
diagnosed (months) 




Mi xed Race 
Associated connective 
t i ssue disease 
Smoking 
Previously pregnant 
Number of pregnancies 
Oral contraceptive 
PPH TPH p 
38 16 
33.7+13.4* 45.7+12.A* <0.05 - -









2.8+2.7* 5.9+3.7* <0.05 - -
29% 20% 
*=mean+ standard deviation 
~=percentage of group 
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PPH is an uncommon condition. McDonnell noted a prevalence 
of 0.13% in a series of autopsied patients greater than 1 
year of age. <
70 ) By 1977 one thousand cases had been 
reported.< 121 ) Paul Wood reported a frequency of 17 among 
10,000 consecutive cases seen by him with cardiovascular 
disease of all types. Cl
32 ) .,:• 
We traced 38 patients seen at this hospital between 1957 and 
1985. As diagnostic approaches and available facilities 
varied during this period the patients were investigated to 
d i ffering degrees. 
made as follows: 
The diagnosis in the 38 PPH patients was 
Lung histology (heart-lung transplantation): 1 
Autopsy: 4 
Pulmonary angiography and subsequent autopsy: 1 
Pulmonary angiography: 23 
Clinical picture with elevated pulmonary 
artery pressure at cardiac catheterisation: 3 
Family history of angiographically demonstrated 
PPH, clinical picture and elevate~ pulmonary 
artery pressure: 
Clinical picture of PPH with systemic lupus 
erythematosus or systemic sclerosis and no 
evidence of interstitial lung disease on chest 
2 
radiograph or pulmonary function testing: 4 
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An accurate estimation of the true frequency of the condition 
has been hampered in the past by the non-specific symptoms of 
the disease and by the lack of a simple screening test for 
pulmonary hypertension. The recent advent of a newly 
developed non-invasive technique for assessing pulmonary 
artery pressure will be of great benefit 
studies. <21 > 
in future 
The preponderance of young females in our group of adult 
patients accords with the observation by other authors that 
both the sporadic and familial forms of PPH particularly 
affect young women, although neither men nor other age groups 
are exempt. <39 ,G 5 , 93 , 99 ,l 2l,l 23 } This has prompted 
speculation that female hormones or pregnancy-related changes 
may contribute to the pathogenesis of this condition. 
Kleiqer and his colleagues(SG} reported 6 young women who 
developed pulmonary hypertension after taking 
contraceptives for periods from 6 months to 5 years. 
oral 
Three 
of the women had no known predisposition to pulmonary 
hypertension while of the remaininq 3 one had a corrected 
patent ductus arteriosus, one had a family history of 
pulmonary hypertension and one had systemic lupus 
erythematosus. Oakley and Somerville< 80 > reported 3 patients 
with congenital left to right shunts who developed severe 
pulmonary hypertension and shunt reversal 6 months to 2 years 
followinq the commencement of oral contraceptive therapy. 
Postmortem examination of the patients who died in these 2 
series revealed intimal proliferation, medial hypertrophy 
and, in one, angiomatoid lesions with no evidence of 
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thromboemboli in the pulmonary vasculature. Irey and 
Norris(Sl) reported 16 women who developed intimal vascular 
proliferation in numerous sites while under the influence of 
female hormones (5 were pregnant, 4 postpartum and 7 were 
taking oral contraceptives). No evidence of a primary · 
thrombotic aetiology was found nor were similar intimal 
proliferative changes noted in a control group who were 
neither pregnant nor receiving oral contraceptives. 
Although normal pregnant women have a lower pulmonary 
. (127 128) 
vascular resistance than non-pregnant women · ' , a study 
in cattle has shown that pulmonary vascular resistance 
increases durinq pregnancy in a specific subgroup of cattle 
which are susceptible to developing pulmonary hypertension 
and right heart failure at hiqh altitude. This does not 
occur in other catt1e<
73 >. This supports the postulate that 
pregnancy or oral contraceptives may cause or accelerate the 
development of pulmonary hypertension in certain predisposed 
individuals. In this study, however, only 29% of the women 
used oral contraceptives while 79% had had a prior preqnancy. 
These findings are similar to those of Fuster et al and are 
not significantly different from what may be found in a 
normal female population of the same age range<
39 >. 
Raynaud's phenomenon and connective tissue diseases have been 
reported in 7 to 30% of patients with primary pulmonary 
hypertension< 122 , 123 >. Scleroderma, particularly the CREST 
{calcinosis, Raynaud's phenomenon, oesophageal dysmotility, 
sclerodactyly and telanqectasia) variant, systemic lupus 
erythematosus and rheumatoid 
t d
(l4,55,77,82,104,105) 
repor e • 
dermatomyositis and pulmonary 
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have arthritis 
In addition a man 
been 
with 
hypertension with no 
radiographic evidence of interstitial fibrosis but moderate 
· · · t h b t d(ll) restriction on spirome ry as een repor e • Connective 
tissue diseases occurred in 16% of our patients (CREST 
variant of scleroderma 2; systemic lupus erythematosus 3; 
juvenile chronic arthritis 1). The frequent occurrence of 
Raynaud's phenomenon and connective tissue diseases with PPH 
has led to a postulate that autoimmunity might play a major 
role in the aetiology. However, there is only one report of 
an autoimmune mechanism in PPH: the finding of immune 
complexes in the small pulmonary blood vessels of a patient 
with pulmonary veno-occlusive disease(l
9 ). The lack of 
response to corticosteroids or to a combination of prednisone 
and azathiaprine provides further indirect evidence against a 
ma j or role of immunological mechanisms<
24 >. Waqenvoort 
contests the hypothesis that a pulmonary vasculitis due to an 
allergic drug reaction or polyarteritis nodosa may result in 
PPH( 121 , 
122 ) In his series evidence of pulmonary arteritis 
and fibrinoid necrosis only occurred in such patients when 
their pulmonary vessels showed histological evidence of 
longstanding severe pulmonary hypertension, suggesting that 
pulmonary hypertension preceded and precipitated the 
arteritis rather than resulted from it. 
The pulmonary vascular changes may merely be one expression 
of a generalized mechanism for progressive vascular damaqe. 
Wood suggested that vasoconstrictive factors may play a 
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t (l33) par • Increased vascular tone is thought to be the 
. . t . 1 f t ( 31 ) 1n1 1a ac or • 
In primary Raynaud's phenomenon cold stimulation can cause a 
. (35) 
reduction in size of the pulmonary capillary bed • This 
is probably effected by precapillary vasoconstriction. In 
scleroderma the intimal changes in digital, renal and 
pulmonary arteries are similar in some respects(
95 >. Acute 
and chronic constriction of interlobular renal arteries with 
lumina previously narrowed by intimal hyperplasia has been 
suggested as the mechanism underlying the rapid onset of the 
malignant hypertension and renal failure seen in scleroderma 
1 · · (13 > h 'd h' h rena cr1s1s • Furt er ev1 ence to support t 1s t eory 
has been provided by reports of the successful treatment of 
this syndrome with modern vasodilator therapy(l 5 , 7 l). In 
experimental animals intense pulmonary artery vasospasm has 
been shown to result in medial hypertrophy, 
necrosis, pulmonary arteritis and occasional 
lesions (l 72 >. 
fibrinoid 
plexiform 
The association of liver disease with pulmonary hypertension 
was first noted in 1951( 68 >. Initial doubts that this 
association was no more than coincidental were disproved by 
McDonnell et al who showed a prevalence of PPH of 0.73% among 
autopsied patients with cirrhosis compared to a prevalence of 
0.13% among all autopsies( 70 >. A significant difference in 
prevalence 
Pulmonary 
was also noted in their clinical series. 
hypertension can affect patients with portal 
hypertension of any cause. In our series one patient had 
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chronic active hepatitis and a marked portal-systemic shunt. 
Another patient who at 32 developed symptoms referable to 
pulmonary hypertension had had portal vein obstruction since 
early childhood. This was thought to be due to angiomatous
 
malformation of the vein or sepsis of the umbilical cord. 
Portal hypertension is an essential feature of 
the 
association and always precedes the development of pulmonary 
hypertension( 62 >. The interval between the first 
manifestation of portal hypertension and the first 
manifestation of pulmonary hypertension in this patient was 
exceptionally long, the usual interval being 2 to 15 years. 
The presence of portal-systemic shunting (spontaneous or 
surgically created) · favours the development of pulmonary 
hypertension(
62 ). Some authors have attributed the pulmonary 
hypertension to microemboli arising from the portal venous 
territory(?G). However, the histological features in these 
patients are regarded as incompatible with chronic pulmonary 
embolism. In addition, the prevalence of pulmonary 
hypertension is not higher in patients with, than in patients 
without, thrombosis of the portal vein, which would be 
expected if pulmonary hypertension were the consequence of 
microemboli (G
2 ). It is more probable that the pulmonary 
hypertension results from the effect of a vasoconstrictive 
agent or a substance toxic to the walls of the small 
pulmonary arteries that is produced in the splanchnic 
territory, destroyed by the liver in normal subjects, but 
which reaches the pulmonary arteries through portal-systemic 
shunts( 62170 >. 
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This mechanism is comparable to that postulated in the 
pathogenesis of dietary pulmonary hypertension where it has 
been suggested that toxic compounds taken in food, beverages 
or medicines are released from the gut, pass through the 
liver and finally reach and injure pulmonary arteries. 
Alkaloids from the genus Crotalaria and the genus Senecio 
have produced hepatic necrosis and pulmonary hypertension in 
monkeys and rats. However, despite widespread use of these 
plants in herbal remedies and bush teas there has been only 
one report of a possible association between Crotalaria 
1 b . d . . d . 
< 41 > a urno1 es 1ngest1on an PPH 1n man • While Crotalaria 
intoxication causing ' veno-occlusive disease of the liver has 
been well described in Jamaican children, none of the 
patients had evidence of pulmonary vascular disease{S,
6 >. The 
relationship between the ingestion of these substances and 
the development of pulmonary hypertension in man has thus yet 
to be proven. 
Iatrogenic pulmonary hypertension .has been reported in 
association with 3 pharmacological agents. Several cases 
have been associated with the use of phenformin{
36 >. These 
have improved on discontinuation of the drug. Between 1966 




Austria and, to a lesser extent, 
The histological picture was that 
West 
of 
plexogenic pulmonary arteriopathy. Because of a temporal and 
geographical association between this outbreak and the 
distribution of a new appetite suppressing drug, aminorex 
fumarate, and because 80% of the patients reported using this 
agent, a causal relationship was accepted. 
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The epidemic 
subsided within 4 years of the withdrawal of the drug. More 
recently another appetite suppressant, fenfluramine, has been 
associated with 2 cases of PPH which improved when the drug 
was . hd (28) wit rawn. None of our patients gave a history of 
exposure to any of these substances. 
The possibility that certain cases of PPH are familial was 
first suggested in 1927 when two sisters with pulmonary 
atherosclerosis of unknown origin were described by Clarke et 
a1(17). The mode of inheritance was initially postulated by 
Hood and his colleagues to be autosomal recessive with 
incomplete male penetrance(
4 G). Subsequent studies have 
provided evidence for an autosomal dominant pattern of 
inheritance with varying penetrance(GS). Loyd and his 
colleagues described 52 known patients in 14 families and at 
least 9 additional persons who transmitted the gene but who 
are without apparent disease. They cite a case of father to 
son transmission as evidence against an X-linked mode of 
transmission. The infrequent expression of the gene in some 
families remains unexplained. Many cases previously labelled 
as sporadic may well prove to be familial when a more 
extensive family history is obtained. Three families were 
included in our study. In the first, two cousins (one male, 
one female) were affected. The female cousin gave a history 
of pulmonary hypertension in 2 of her 3 sisters. Two 
brothers in the second family developed symptoms in early 
adolescence and died within 2 years. 
younger brother were unaffected. 
An older sister and 
In the third family a 
mother and her daughter developed the condition. 
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Two other 
children were unaffected. Survival of cases of familial PPH 
is similar to that f 
( 65) 
of the sporadic orm • The 
pathogenesis in these cases is uncertain. A 
fibrinolytic activity has been noted in one 
defect in 
affected 
f ·1 (50) am1 y • 
It has been suggested that the hypercoagulable state 
attributable to the lupus an~icoagulant and associated 
anticardiolipin antibodies plays a causative role in the 
genesis of PPH( 2 ). Anticardiolipin antibodies were noted in 
3 of 10 patients reported by Sleeper(ll
3 ) and in 2 of 23 in a 
second series( 123 ). Asherson et al detected the lupus 
anticoagulant in 5 of 6 patients with systemic lupus 
h . d 1 h . (
2 ) eryt ematos1s an pu monary ypertens1on • 
Pulmonary hypertension due to widespread obliterative 
arteriolitis secondary to the deposition of schistosomal ova 
occurs in 2.1% of all cases of bilharzia(ll
0 ). Although some 
of our patients came from areas where bilharzia is endemic, 
none gave a history or showed features of infection, and no 
ova were found in those patients whose lung tissue was 
examined histologically. 
Thromboembolism has been suspected to play a significant 
causative role in PPH( 122 ). Obstruction of the muscular 
pulmonary arteries and arterioles rather than the larger 
elastic ones is the form of recurrent thromboembolism that 
1 .. 11 (3
1,39,122) c 1n1ca y appears as PPH • It is characterized by 
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an insidious onset with a relentless course of progressive 
dyspnoea and is quite unlike the presentation of patients 
with recurrent embolism to large ·pulmonary arteries. Such 
patients tend to have a step-like clinical course with acute 
exacerbations of dyspnoea and chest pain with intervening 
periods during 
stable( 93 ). 
which effort tolerance remains reasonably 
Our study confirms previous reports that 
patients with chronic large vessel thromboembolic disease 
tend to be older than those with PPH. The mean ages (with 
ranges) of 46(28 to 73) and 34 (13 to 58) years respectively 
were almost identical to those noted in previous studies. 
The long 
group is 
duration of symptoms before diagnosis in the 
· d · h . d' (3,39,123) 1n accor wit previous stu 1es 
PPH 
and 
suggests that the disease process was well advanced before 
the diagnosis was made. Early diagnosis is difficult to 
achieve where the initial symptoms are relatively non-
specific. The trend towards a shorter duration of symptoms 
before diagnosis in the large vessel TPH group was not 
significant. 
Two patients in the TPH group were at high risk of developing 
thromboembolic disease: one had polycythaemia rubra vera 
while the other was deficient in anti-thrombin III. 
risk factors were present in the PPH group. 
No such 
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VIII B: Clinical Features: 
VIII B(i): Symptoms and Signs: 
Table VIII B(i): Symptoms and signs of patients studied: 
Number 
Dyspnoea on exertion 
Severity of dyspnoea 
(NYHA Classification) 
Chest pain 











Right ventricular third 
heart sound 

























































Dyspnoea on exertion was the most frequent symptom, oc
currinq 
in R8~ of the PPH patients. These had a mean NYHA qra
dinq of 
2.7+0.R (mean + SD). 
vertiqo or syncope. 
Forty-three per cent complained of 
This appears to result from diminished 
cerebral blood flow due to an inability to increase 
cardiac 
output during exertion because of a fixed high pu
lmonary 
resistance(
29 ). The anqinal chest pain that occurred in 32% 
of our patients has been ascribed to riqht ven
tricular 
subendocardial ischaemia secondary to hypoperfusi
on of 
hypertrophied myocardium and a diminished perfusion q
radient 
lt · f 1 d · h · 1 
11 · ni 2 ) 
resu 1ng rom e evate r1q t ventr1cu ar wa tensio
n • 
The association of Raynaud's phenomenon with PPH 
(as 
discussed in section VIII A) occurred in 22% of our pa
tients. 
The symptoms experienced by our patients are similar t
o those 
reported by other auth
ors. (23,48,113,123) Raynaud's 
phenomenon and arthritis were not noted in the TPH aro
up, but 
they were similar to the PPH patients in other respec
ts. 
The most frequently observed clinical sign in the PPH
 group 




This was observed in all but one (97%) of our 
However this was not a blinded study and the 
accuracy and independence of this observation from other 
siqns cannot he assessed from this study. The other fea
tures 
as outlined in ~able VIII B(i) 
previous studies. ( 23 , 113 ,
123 ) 
are similar to those found in 
The clinical findings in the 
TPH group differed in two respects only: there was
 a 
hiqher incidence of lower extremity varicose veins 
(p<0.01) 
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and in none of the TPH patients was 
a right ventricular 
fourth sound noted {p<A.01). 
. . t a· {3,23) in previous s u ies 
The last finding was not noted 
and as no reason for this is 
apparent it is probably a chance findin
g due to the potential 
for error implicit in retrospective 
documentation of the 
observations of a large number of phys
icians. 
VIII B{ii): Chest radiographic features: 
Table VIII B{ii): Chest radiographic features of the 
patients studied. 
PPH TPH 
Number 38 16 
Enlarged proximal pulmonary 
arteries 89% 81% 
Cardiomegaly 82% 69% 
Attenuation of peripheral 
vessels 60% 56% 
Pleural effusion 3% 13% 
Venous congestion 0% 13% 










The most frequently noted abnormality was enlargement of the 
proximal pulmonary arteries. This was noted in 89% of our 
patients. Cardiomegaly, frequently with features 
characteristic of right ventricular enlargement, occurred in 
82%. In 60% of patients peripheral vascular markings were 
attenuated. There was no evidence of venous congestion or 
lymphatic distension. Previous studies noted a slightly 
higher frequency{90-100%) of enlargement of the proximal 
pulmonary arteries but were otherwise similar{
2311131123 ). 
The TPH group had essentially similar chest radiographic 
features. Anderson and his coworkers observed that in 
primary pulmonary hypertension the pulmonary artery is 
usually considerably enlarged, while in thromboembolic 
pulmonary hypertension it was more often normal or only 
slightly enlarged. Although our findings were different we 
were limited by not being able to trace some chest films for 
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personal review and therefore having to rely on the formal 
report issued by the radiologist at the time. We therefore 
cou ld not ensure uniformity of diaqnostic criteria. 
VIII B(iii): Electrocardioqraphic features: 
Table VIII B(iii): Electrocardiographic features of the 
patients studied: 
PPH TPH 
Number 37 16 
Sinus Rhythm 97% I 94% 
Right ventricular 
hypertrophy 73% 3R% 
Right ventricular strain 65% 50% 
Right axis deviation 94% 69% 
Riqht atrial enlargement 39% 25% 
Pseudo left atrial enlarge-
ment 0% 6% 
Right bundle branch block 28% 25% 




The abnormality most frequently noted in the PPH group was 
right axis deviation which occurred in 94%. The frequency of 
occurrence of right ventricular hypertrophy (73%) and right 
atrial enlargement (39%) was lower than that noted in 
previous studies( 23 , 4S,ll 3 ,i 23 ). In comparison with those 
reports our patients had a higher incidence of right bundle 
branch block. 
rhythm. A 
All but one of our patients were in sinus 
significantly lower frequency of riqht axis 
deviation (p <0.05) and right ventricular hypertrophy 
(p <0.05) was noted in the TPH qroup. This is in agreement 
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with previous observations of a lower prevalence of these two 
f eatures in patients with chronic thromboembolic pulmonary 
hypertension( 3 , 23 >. 
VIII B(iv): Pulmonary function tests, arterial blood gas and 
haematocrit measurements. 
Table VIII B(iv): Pulmonary function tests, arterial blood 
gas and haematocrit measurements in the 
patients studied (mean+ SD) 
PPH TPH p 
n = 19 n = 6 
FVC (% predicted) 81%+17% 91%+16% - -
FEV1
/FVC 80%+12% 73%+9% - -
TLC (% predicted) 84%+15% 107%+9% <0.05 - -
RV/TLC 34%+8% 38%+5% - -
TLCOSB 52%+16% 72%+33% - -
KCO (% predicted) 67%+27% 90%+21% - -
P0 2 (kPa) 
10.6+2.0 10.3+2.l - -
PC0
2 (kPa)
 4.1+0.9 4.3+0.8 - -
Haematocrit 0.44+0.HI 0.45+0.06 - -
FVC = forced vital capacity; FEV1/F
VC = ratio of forced 
expiratory volume in one second to forced vital capacity; 
TLC= total lung capacity; RV/TLC= ratio of residual volume 
to total lung capacity; TLCOSB = transfer factor for carbon 
monoxide (by the single breath method); KCO = transfer 
factor for carbon monoxide per litre of alveolar volume. 
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Williams and his colleagues asserted that lung volumes are 
generally normal in patients with pulmonary hypertension 
secondary to pulmonary vascular disease and that restrictive 
more likely due to interstitial lunq changes are 
dis ease (1 29 ) • This opinion was challenged by the findings of 
Horn et al that a significant proportion of their patients 
with both primary and thromboembolic pulmonary hypertension 
~- d . . t"l t tt ( 47 ) Th . demonstrate ~ restrictive ven i a ory pa erns • eir 
study relied only on radiographic a~d clinical exclusion of 
interstitial lung disease. This is unfortunate as Epler and 
his colleaques demonstrated that almost 1~% of their patients 
with histologically confirmed diffuse infiltrative lung 
diseases had normal chest radiographs. <
33 ) Nevertheless, 
that restrictive changes can occur in primary pulmonary 
hypertension without histological evidence of interstitial 
fibrosis was shown by the case reported by Scharf et al <
107 ). 
Burke et al noted a mean total lung capacity of 82. 2% · of 
predicted in 18 patients with primary pulmonary 
hypertension< 9 ). 
In order to ensure that no patient with pulmonary 
hypertension caused or aggravated by interstitial or 
obstructive lung disease influenced the results of this 
study, all those whose total lung capacity (TLC) , forced 
vital capacity (FVC) or forced expiratory volume in one 
second to forced vital capacity ratio (FEV1
/FVC) was less 
than 2 /3 the predicted value were excluded. Some patients 
with restrictive changes due to pulmonary vascular disease 
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alone may have been excluded on this basis. However, as lung 
histology was not available in the majority of these cases, 
th i s was the only means of selecting a group of patients 
whose clinical course was uninfluenced by the coexistence of 
interstitial lung disease. Despite this our findings show a 
small but significant restriction of lung volumes in the PPH 
group when compared with the TPH group (which had volumes 
close to predicted values). The mean transfer factor for 
carbon monoxide (TLC08B) 
was below predicted in both 
groups. The mean value of 52% predicted in the PPH group 
was similar to the results of both Williams et al <
129 >. and 
Horn et al <47 ) but less than the value of 71.8% predicted . 
noted by Burke et a1<
9 ). The mean TLC0 88 in
 our TPH group 
was intermediate between the values found in previous 
t d . ( 2 3, 47,129) A t . 1 PO d C 
1 . . 1 
s u 1es • r er1a . 2 an P o 2 va ues
 were s1m1 ar 
to those noted in previous studies of PPH patients<
47 , 129 >. 
Benotti noted a slightly lower mean Paco 2 i
n his patients 
with chronic thromboembolic pulmonary hypertension<
3 ). Mean 
haematocrit values were within the normal range in both 
groups. 
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VIII B{v): Radionuclide lung scans: 
Table VIII B{v): Radionuclide lung scan data in the patients 
studied: 
Total number of patients 
Number {% of total) patients 
who had scans 






Angiogram + catheterization 
+ histology 



























* One had SLE, the other the CREST variant of scleroderma. 
No history of thromboembolism. 
The successful use of pulmonary artery embolectomy in 
selected patients with chronic large vessel thromboembolic 
pulmonary hypertension<
3 , 23 , 74 , 75 ,ll 5 ), and of vasodilator 
therapy in some patients with PPH has made accurate diagnosis 
of the two conditions essential. The increased risks 
associated with pulmonary artery catheterization and open 
lung biopsy in this group of patients<
39 ,II 4 ) have prompted 
the investigation of non-invasive means of identifying these 
conditions. Lung perfusion scanning using labelled 
macroaggregated human albumin provides an effective method of 
investigating the pulmonary circulation. Wilson et a1<
130 ) 
and Fishman et a1< 37 ) have shown that segmental or larger 
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defects occur in TPH whereas PPH patients either have a 
normal scan or show multiple bilateral subsegmental "patchy" 
areas of decreased perfusion. Wilson et al observed filling 
defects in the capillary blush between the arterial and 
venous phases of the pulmonary angiograms corresponding to 
these patchy areas and ascribed them to either primary 
pulmonary hypertension with secondary in situ thrombosis, 
small vessel thromboembolism, a combination of the two or a 
new as yet unidentified pathological entity. On the basis of 
a subsequent study Fishman et al classified patients with 
such patchy scans clearly in the category of primary 
pulmonary hypertension(
37 ). Nihill and McNamara noted 
similar filling defects in the capillary blush during 
angiography in patients with congenital left to right shunts 
and identified them as being indicative of elevation of 
pulmonary vascular resistance(?S). It is possible that they 
merely reflect a more severe degree of occlusive change in 
the small pulmonary vasculature. 
Similar lung scan findings have been noted in PPH by D'Alonzo 
et a1( 23 ). Our findings confirm these reports. All of the 
TPH patients who were studied had scans indicating a high 
probability of pulmonary embolism. Of the 11 patients 
studied in the PPH group, 4 had features indicative of a low 
probability of pulmonary embolism only while the other 7 had 
normal scans. No ventilation defects were noted in any of 
the 10 patients who had ventilation and perfusion scans. 
The nature of the underlying condition was 
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identified 
histologically or by pulmonary angiography in 17 of the 19 
patients who were scanned. The two other patients had 
catheter proven pulmonary hypertension in the setting of a 
connective tissue disease (SLE and the CREST variant of 
scleroderma) with no evidence of interstitial lung disease 
clinically, radiographically or on pulmonary function testing 
and with no history suggestive of preceding episodes of 
thromboembolism. They were thus assumed to have primary 
pulmonary hypertension. 
Although four fatalities have been reported in patients with 
obliterative pulmonary hypertension after perfusion 
scanning(lG,l 30 >, no adverse effects were noted in 
lung 
our 
patients. A similar absence of complications has been noted 
by other authors( 23 , 37 ,l
30 >. Perfusion lung scanning has 
proved to be a safe and effective means of distinguishing 
primary pulmonary hypertension from chronic large vessel 
thromboembolic pulmonary hypertension. 
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VIII B(vi): Pulmonary angiography and lower limb venography: 
Table VIII B(vi): Pulmonary angiograms and lower limb 
venograms in the patients studied: 
PPH TPH p 
Number of patients studied 
(% of group) 22(58%) 15(94%) 
Pulmonary angiograms: 
Dilation of proximal 
pulmonary arteries 67% 80% 
Filling defects in main 
or lobar pulmonary 
arteries 0% 100% <0.001 
Small vessel occlusion 80% 47% <0.05 
Normal 10% 0% 
Lower limb venograms: 
Evidence of deep venous 
thrombosis 0% 57% <0.01 
None of the 22 PPH patients in whom pulmonary angiography was 
performed showed evidence of filling defects in the main or 
lobar pulmonary arteries. Generalised peripheral small 
vessel pruning was noted in 80%. Two-thirds showed 
dilatation of the main and proximal lobar pulmonary arteries. 
Pulmonary angiograms were normal in 10%. A slightly higher 
frequency of proximal artery dilatation was noted in the 
study by Fuster et a1< 39 >. The angiographic features of 
their group were otherwise similar. 
Occlusion of the main or proximal pulmonary arteries was 
demonstrated in all of the 15 TPH patients studied, but only 
47% showed features of peripheral small vessel occlusion. 
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This was significantly lower than in the PPH group. Proximal 
dilatation occurred in 80%. 
Microarteriographic techniques utilizing pulmonary wedge 
angiography have been suggested as a means of assessing the 
. (78) 
severity of the abnormal pulmonary haemodynam1cs , and of 
distinguishing PPH from small vessel thromboembolic pulmonary 
. 992 117) 
hypertension ' • Pulmonary arteriographic studies on 
autopsy specimens suggested that PPH caused selective loss of 
arteriolar segments 100u to 280u in diameter whereas small 
vessel thromboembolic hypertension involved arterioles of 
less than 60u diameter(
92 >. This has been challenged by 
clinical studies that have shown occlusion of vessels from 
1 .5 to 2 mm diameter in some cases of thromboembolism(ll
7 ). 
None of our patients was subjected to pulmonary wedge 
angiography. 
Several reports have stressed the increased risks associated 
with cardiac catheterization and pulmonary angiography in 
these patients( 2G,ll 4 ,l 26 >. Of the 120 PPH patients 
subjected to catheterization by Fuster and his coworkers, 5 
died as a result of the procedure. (
39
> Transient severe 
pulmonary hypertension following the injection of the 
radiographic contrast medium used in this procedure has been 
r eported and probably occurs more frequently than is 
generally recognized as most centres do not measure pulmonary 
artery pressures continuously during pulmonary 
angiography(26,114,126). The mechanism by which cardiac 
arrest is caused in this situation has not been fully 
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elucidated. It may be due to reflex pulmonary 
vasoconstriction following injection of the dye, sludging of 
red blood cells in small pulmonary vessels(
2G) or a cardiac 
arrhythmia initiated by transient coronary artery hypoxaemia 
as a bolus of contrast medium passes(ll
4 ). No adverse effects 
of cardiac catheterization or pulmonary angiography occurred 
in our patients. 
Ascending lower limb venography was normal in all 5 PPH 
patients on whom it was performed. A significantly higher 
proportion (57%) of the 7 TPH patients who were studied 
showed evidence of deep venous thrombosis. 
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VIII B(vii): Haemodynamic data at diagnosis: 
Table VIII B(vii)a: Haemodynamic data at diagnosis in the 
patients studied (mean+ SD) 
Number of patients studied 
(% of group) 
Mean pulmonary artery 
pressure (mmHg): 
Mean systemic blood 
pressure (mmHg): 
Mean right atrial 
pressure (mmHg) 
Pulmonary capillary wedge 
pressure (mmHg) 
Cardiac output (1/min) 
Cardiac index (1/min/m2 ) 
Stroke volumi index 
(ml/beat/m) 












Systemic vascular resistance 
(units) 22.8+7.8 
Ar t erial oxygen saturation 
















Mea n pulmonary artery pressure was significantly greater in 
the PPH oroup. A similar trend noted by D'Alonzo et al did 
not attain statistical significance( 23 >. 
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The greater ventilation/perfusion mismatching produced by 
pulmonary thromboembolism is reflected in the significantly 
lower arterial oxygen saturation in this group. 
The haemodynamic findings in the PPH patients studied by 
Hughes and Rubin( 4S) and Fuster et al (
39
> as compared with 
the findings of 
Table VIII B(vii)b. 
the present study are outlined in 
Table VIII B(vii)b: Haemodynamic data of PPH patients 
compared with previous studies 
(mean +SD) 
Present Hughes Fuster 
study & Rubin et al 
Mean pulmonary artery 
pressure (mmHg) 64.5+18.7 57.8+13.6 64 - -
Cardiac output (1/min) 4.2+1.4 4.0+1.8 - -
Cardiac index (l/min/m2 )
 2.7+1.0 2.2 -
Pulmonary vascular 
resistance (units) 15.2+9.3 14.5+7.3 - -
Arterial oxygen saturation 
( % ) 94.4+2.6 91 -
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Benotti and his colleagues found a fair correlation 
( r = 0.65) between the severity of the pulmonary hypertension 
and the severity of arterial hypoxaemia in 15 patients with 
TPH( 3 ). We found no correlation between the resting mean 
pulmonary artery pressure and ~he transfer factor for carbon 
monoxide in our group of patients. (Fig. VIII B[i]) 










RESTING PA p vs TLCOsa IN 
PRIMARY PULMONARY HYPERTENSION 
• 
• • • • 
• 
• • • • • 
• ... 
r = 0·31 
t = 1 · 16 
p>0·1 
n= 14 
30 40 50 60 70 
TLC058 (% PREDICTED> 
80 
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VIII C: Exercise Studies: 
Four patients were subjected to a stage 1 exercise study at 
the time of diagnosis. They achieved a mean maximal power 
output of 56% predicted with a range of 43 to 74%. The mean 
arterial desaturation on exercise was 3.3% with a range of 0 
to 9%. All showed an excessive heart rate response which 
app roached the predicted maximum heart rate. A sub-normal 
blood pressure response occurred in two patients. Three 
patients showed mild hyperventilaton and tachypnoea 
throughout the test. In the case of the 4th patient, 
ventilation was initially normal but later rapidly 
to approach the predicted maximum. Exercise was 





5th patient whose initial exercise test was 
abandoned as she became hypotensive within three minutes of 
commencing exercise was again tested 3 years after diagnosis 
and provided additional data which was included in the 
assessment of the correlation of resting PETco 2 
percentage predicted power output attained (Fiq. 
with 
VIII 
C[ i ii]). No correlation was noted between the percentage 
predicted maximum power output achieved and the resting mean 
pulmonary artery pressure, right atrial pressure or stroke 
volume index. There was no correlation between the 
per centage desaturation on exercise and the resting mean 
pu l monary artery pressure (Fig. VIII C[i]). 
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Fiq. VIII C[i] A: Resting mean pulmonary artery pressure 
(PAP) , B: Mean right atrial pressure (RAP), and C: Stroke 
volume index plotted against% predicted maximal power output 
attained in the 4 patients tested. Mean RAP was not recorded 
in one patient. D. Resting mean pulmonary artery pressure 
plotted against% desaturation on exercise. 
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Fig. VIII C[ii]: End tidal PC0 2 during exercise vs stage of 
exercise as reflected by% predicted maximum power output as 
measured in patients 2, 6, 8 and 32. End tidal Pco
2 
is low 
at rest and at various stages of exercise. 
PET CGi VS 




PET CO2 25 
::1 
6 
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Fig VIII C[iii]: 
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Resting end tidal Pco 2 vs % predicted 
maximum power output as measured in patients 1, 2, 8, 25 and 
32 . No correlation was noted. 
RESTING PET CO2 vs 
l 
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During exercise the PETC02 was depressed earlier and to 
greater degree than in normal subjects in . whom the PET CO 2 
would show little or no change at comparable levels of 
. (53} exercise (Fig. VIII C[ii]}. This is probably due to an 
increase in physiological dead space caused by pulmonaty 
vascular disease. 
Moreover there was no correlation between the resting PETco 2 
and the percentage predicted maximal power output attained 
(Fig VIII C[iii]}. 
We were thus unable to show any correlation between the 
parameters measured during stage 1 exercise studies and the 
severity of the pulmonary hypertension at diagnosis in these 
patients. 
Stage 1 exercise studies were repeated in 3 patients. A 
patient with CREST variant of scleroderma who had noted 
progressive worsening of dyspnoea on effort showed a 60% 
r ·eduction of maximal power output and a more severe 
tachycardia during exercise compared with a test done 3 years 
earlier. The second patient had PPH associated with previous 
chronic active hepatitis. Her effort tolerance had remained 
good and a repeat exercise study showed that only a slight 
reduction in maximal power output had occurred during the 
3 1/2 years since the previous study. The last patient had 
PPH associated with SLE. She described a mild improvement in 
her effort tolerance. Her maximal power output was 
moderately improved. It would therefore appear that the 
a 
patients' subjective assessment of exercise 
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tolerance 
reflected measured exercise capacity with a fair degree of 
accuracy. As repeat catheterizations were not performed on 
these patients we were unable to assess whether changes in 
maximal power output parallelled changes in pulmonary 
vascular involvement as has been suggested by Janicki et 
al(52). 
VIII D: Response to vasodilator therapy. 
The observation that medial hypertrophy of the muscular 
arteries and muscularization of the arterioles is the initial 
structural abnormality in PPH has led to the postulate that 
the primary 
(31,122,132) 
defect is probably prolonged vasoconstriction 
This has prompted the use of vasodilator 
agents in an attempt to reverse the vasoconstriction before 
irreversible changes develop. Dresdale described the use of 
vasodilators in his early paper on this subject(
29 >. More 
recently, a number of papers have described beneficial 
effects from the use of vasodilators( 12 , 66 , 67 , 86 ,1°1,125). 
We evaluated the effects of 10 vasodilator agents in 13 
patients. Not all patients were treated with the same agents 
as treatment policy was modified during the study period. 
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Table VIII D(i): Vasodilator agents evaluated: 
Patient: 1 2 8 9 13 16 21 22 23 25 30 31 32 
Hydrallazine + + + 
Isosorbide ~ 
Di nitrate + + + + 
Isoprenaline + + + + 
Nifedipine + + + + 
Amyl Nitrate + + + + 
Phenylephrine + + + 





VIII D(i): Hydrallazine: 
Fig. VI I I D ( i) : Acute effect of hydrallazine in the 3 
patients tested: 
HYDRALLAZINE 




Hydrallazine (50mg by mouth) was given to 3 patients. Two 
had a significant (greater than 10%) reduction in pulmonary 
vascular resistance (PVR) while a significant rise occurred 
in the third. None of the patients showed a significant 
reduction in mean pulmonary artery pressure (PAP). One 
showed a 25% elevation. Mean systemic blood pressure (SBP) 
remained relatively constant: 
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a significant reduction of 
systemic vascular resistance (SVR) in two patients was 
compensated by a significant elevation in cardiac index (CI) 
which was achieved by a compensatory tachycardia in one and 
an increase in stroke volume index (SVI) in the other. In 
the third patient the CI remained stable as a significant 
increase in stroke volume index was compensated by 
significant reduction in heart rate. 
Rubin and Peter noted a reduction of PVR with a concomitant 
increase in cardiac output (CO) both at rest and on exercise 
in 4 patients treated with this agent. There was no change 
in mean pulmonary artery pressure. These effects persisted 
after follow up for 3 to 6 months< 102 >. Lupi-Herrera et al 
identified a subgroup of their patients with PAP <60 mmHg, 
PVR <15 units/m
2 
and PVR/SVR ratio <0.7 who showed a similar 
response to hydrallazine while the remainder (who had a 
higher PAP and PVR) showed a significant reduction in SVR 
1 
(67) 
on y • 
Adverse effects of hydrallazine have been 
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frequently 
reported. Kronzon et al reported a rise of PAP in 2 patients 
due to an increase in cardiac output in the face of an 
unchanged pulmonary vascular . (60) resistance. Four of the 
patients studied by Packer and his colleagues became 
symptomatically hypotensive within 24 hours of the initiation 
of therapy. One of these patients died(SS). Severe 
hypotension occurred in one of the patients studied by 
Hermiller et. a1< 44 >. 
There would thus appear to be a group of patients with a 
responsive pulmonary vasculature who benefit from 
hydrallazine therapy. However, the use of this agent in 
patients with a fixed pulmonary vascular resistance may be 
hazardous. Direct haemodynamic monitoring is essential in 
all patients during a trial of therapy. 
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VIII D(ii): Isosorbide dinitrate: 
F ig VI I I D (ii) : Acute effect of isosorbide dinitrate in the 
4 patients studied: 
ISOSORBIDE DINITRATE 





.- . 20 
·40 
Isosorbide dinitrate 10 mg orally was given to 4 patients. 
Two showed a significant reduction in PAP. Although the PAP 
in the third patient was unchanged, the PVR was significantly 
reduced. Two patients had significant reductions of SBP and 
SVR. The effect on heart rate, CI and SVI was inconsistent. 
• 
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Our findings are in accord with those of Hermiller and his 
colleagues( 44 > who showed that isosorbide dinitrate was the 
only one of 6 vasodilators tested to achieve a significant 
reduction of both PAP and PVR. Pearl and his coworkers 
found a similar significant reduction in both PAP and PVR in 
9 patients with pulmonary hypertension. Five of their 6 
patients on long term therapy experienced an improvement in 
their symptoms. Isosorbide dinitrate, unlike other 
vasodilators, produces systemic venodilatation and probably 
pulmonary arterial dilatation at a dose that produces only 
minimal systemic arterial dilatation(
86 ). This may account 
for the relative freedom from the systemic hypotension which 




VIII D{iii): Nifedipine� 
Fig. VIII D{iii): Acute effect of nifedipine in the 4 
patients studied: 
NIFEDIPINE 
PAP PVR SBP SVR Cl HR SVI 








No signi�icant reduction in PAP or PVR occurred in the 4 
patients treated with 20 mg of nifedipine sublingually. A 
significant elevation of PAP occurred in 1 patient due to a 
mild increase in both PVR and CI while another patient showed 
a significant increase in PVR associated with a significant 
decrease in cardiac index. Systemic blood pressure was 
significantly reduced in 2 patients. 
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Camerini and his coworkers were the 
first to report a 
pronounced fall in PVR and SVR with 
a rise in CO after 
sublingual nifedipine in a patient with
 severe PPH. This 
was accompanied by a marked improvemen
t in symptoms and was 
f 11 
. d(12) 
maintained over the 3 month o ow up p
er10 • Beneficial 
acute and long term haemodynamic ch
anges associated with 
improvement in , symptoms were achieved 




late stage PPH studied by De 
Similar haemodynamic 
nifedipine were noted by Rubin 
et al 
Feyter and his 
changes after 
in their 9 
patients. (l 0 l) 
equilibrium 
Heart rate and PAP did not change 
but 
gated blood pool radionuclide 
imaging 
demonstrated a reduction in right vent
ricular end-diastolic 
and end-systolic volumes with an increas
ed right ventricular 
ejection fraction indicative of improv
ed right ventricular 
performance associated with the redu
ction in PVR. These 
effects persisted after follow up perio
ds ranging from 4 to 
14 months. Other authors have also report
ed the beneficial 
haemodynamic effects of nifedipine ther
apy(Sl,l
3 l). 
However, not all reports have been as e
ncouraging. Dalal and 
his colleagues reported the onset of 
azotaemia and right 
ventricular failure in a 23 year old
 woman when the 
nifedipine dose was doubled after an 
initially encouraging 
response to 10 mg three times daily. She die
d a day later. 
The authors postulated that the negative
 inotropic effect of 
the nifedipine 
d 
. . (22) 
eter1orat1on • 
may have played 
Berken boom found 
a part in her 
no haemodynamic 
improvement after nifedipine administrat
ion to a 36 year old 
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woman with PPH(
4 ). Our findings were in agreement w
ith those 
that failed to show any benefici
al effect of nifedipine 
therapy. 
Other calcium antagonists 
have been evaluated in the
 
management of this condition. 
Kambara and his colleagues 
showed that diltiazem effected a si
gnificant reduction in PAP 
and PVR and a significant inc
rease in CI when given 
intravenously and, subsequently
, orally over eleven 
months(S
4 ). Landmark et al noted that intrav
enous verapamil 
caused a slight reduction in PAP bu
t that in some patients it 
exerted a marked negative inotropic
 effect with a concomitant 
. . ( 61) 
increase 1n PVR • 
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VIII D(iv): Isoprenaline 
Fig. VIII D(iv): Acute effects of
 isoprenaline in the 4 
patients tested: 
ISOPRENALI NE 
-PAP PVR SBP SVR Cl HR SVI 
40 
Four patients were treated with
 isoprenaline: 
treated with an intravenous in
fusion while the 
two were 
others 
received 15 mg sublingually. I
n all three patients in whom 
these parameters were measu
red, PVR and ,SVR showed 
significant reductions while the 
cardiac index and heart rate 
increased significantly. Only o
ne patient showed a 
significant reduction in PAP. In
 two patients the PAP 
increased significantly as the
 reduction in PVR was 
insufficient to compensate for the 
increase in CI produced by 
isoprenaline. The PAP remaine
d constant in the fourth 
patient despite a significant 
reduction in PVR. An 
-
additional patient who was given
 intravenous isoprenaline 
developed a severe tachycardia wh
ich precipitated right 
ventricular failure. No haemodyna
mic readings were recorded. 
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Other authors have reported si
milar results. Le
e and his 
colleagues observed a reductio
n of PVR and increase of Cl 
after 20 mg sublingu
al isoprenaline in 14 
patients(
63 ). 
Hermiller et al reported a reduc
tion in PVR, SVR and SBP with 
' ' ' d . h . t . 
t ( 44 ) D d t 
an increase in cardiac in ex in
t eir pa ien s • aou e 
al showed a reduction in 
PVR in 5 of their 6 
. ( 24) 
patients • 
Shettigar and his cowork
ers' report of an in
itially 
f avourable response but subseque




maintenance therapy into questio
n. 
brought the efficacy of 
However both Pantano(
9S) 
. ( 88) 
and Pietro et al have subs
equently reported persistent 
haemodynamic and . symptomati
c benefit from long term 
administration of sublingual iso
prenaline. The study by Lupi 
Herrera et al purported to shed 
some light on the marked 
variability of the response t
o isoprenaline in different 
patients: only those patients w
ith a moderately elevated PVR 
responded; those with severely 
elevated PVR did not respond. 
The authors suggested that non-r
esponders represented a more 
advanced stage of the disease 
process. (
66 ) However, the 




VII I C ( V) : Di a Z OX i de: 
Using the treatment protocol first suggested by Wa
ng et 
a1< 125 ) we noted a significant reduction in PVR in 3 of th
e 4 
patients who were treated with this agent. 
One of these 
showed a significant concomitant reduction of PAP wi
th no 
change in SBP, SVR or CI while the other 2, i
n whom PAP 
remai ned unchanged, showed a significant reduction in SV
R and 
SBP accompanied by a significant increase in CI. One pat
ient 
developed severe hypotension with confusion and sinus a
rrest 
after intravenous injection of 300 mg of diazoxide. 
Other authors have noted similar responses with a red
uction 
. d s . d b . . co ( 5 8 ' 12 5 ) 1n PVR, SVR an BP accompan1e y an increase 1n • 
Hermiller et al noted in addition a rise in PAP due 
to an 
increase in cardiac output disproportionate to the red
uction 
in PVR( 44 ). 
Serious side effects have been noted following administ
ration 
of diazoxide. Of three patients to whom this agen
t was 
administered by Buch and Wennevold one developed asy
stole, 
one developed total atrioventicular block and the 
third 
severe systemic hypotension(S). Rubino and developed 
Schroeder reported a patient who developed ventric
ular 
tachycardia and died shortly after injection of 300 
mg of 
d . ' d (103) lZOXl e . Elkayam noted severe hypotension and 
supraventricular tachycardia following injection of a s
imilar 
dose <32 ). 
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The high risk of serious 






f this agent. 
VIII F(vi): Prazosin 
While other authors have fou
nd this effective in reducin
g PVR 
and PAP and increasing co(
32 ), we noted no significant e
ffect 
after giving 0.5 mg orally t
o a single patient. 
VIII D(vii): Other agents: 
Amyl nitrate, acetylcholine
 and labetolol had no signif
icant 
effect on PAP and PVR. 
Acetylcholine has been no
ted 
previously to produce an inc
onsistent response with no e
ffect 
on the resting cardiac out
put(
90 , 106 >. Amyl nitrate and 
labetolol caused a marked
 reduction SBP and SVR 
while 
phenylephrine caused a signi
ficant rise in PAP and PVR i
n the 
2 patients to whom it was ad
ministered. 




l, were not used in our st
udy. 
Prostacycline has been show
n to reduce PVR, PAP and SB
P as 
well as preventing platelet 
aggregation within the pulm
onary 
vascular bed(llG). A contin
uous infusion over 13 months
 has 
been effective in treating
 a woman with PPH(
45 >. Other 
investigators have found it
 a useful agent in assessing
 the 
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responsiveness of the pulmonar
y vascular 
bed(ll2). The 
ability to titrate the dose against the haemo
dynamic effect, 
the potency of this agent as a pulmonary vas
odilator and the 
ability to reverse rapidly any adverse haemo
dynamic effects 
by discontinuing the infusion suggest that it
 is particularly 
suitable for the initial testin
g of a patient's 
responsiveness to vasodilators. Se
vere side effects of 
nausea, headache and cutaneous flushing
 prevent its 
. (100) 
utlization in a number of patients • 
The serum angiotensin-converting enzyme inhib
itor, captopril, 
was initially reported to relieve symptoms an
d improve right 
ventricular performance in patients with P
PH(
49 >. Other 
authors have subsequently shown no significa
nt effect on the 
pulmonary vasculature in the majority of 
their patients 
t t d .
 h h ' (64,94) rea e wit t 1s agent • 
Unlike other authors we were unable to iden
tify a group of 
patients who consistently responded to the 
various agents 
tested in our study. Different agents show
ed different 
degrees of effectiveness in different p
atients. While 
isoprenaline, diazoxide and isosorbide din
itrate were 
reasonably effective in reducing PVR, thei
r effect on 
pulmonary artery pressure was less consisten
t. 
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VIII D(viii): Future possibilit
ies: 
Vasodilator therapy may be effe
ctive in a larger proportion 
of PPH patients if they are 
diagnosed before irreversible 
changes develop in the pulmona
ry arterioles. Non-invasive 
measurement of pulmonary artery 
pressure by doppler promises 
to be a valuable means of 
detecting 
. (21) 




uction of pulmonary artery 
pressure is limited by the seve
re systemic effects produced 
by vasodilator agents currently
 available. The development 
of an agent acting selectively 
on the pulmonary vasculature 
and which could be administere
d orally would be a great 
advance. 
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VIII E: Clinical course: 
VIII E(i): Primary and chronic l
arqe vessel thromboembolic 
pulmonary hypertension: 
Adequate follow up information to
 40 months was available on 
28 patients in the PPH group and 
9 patients in the TPH group. 
The characteristics and surviva
l curves of the two groups 
were analyzed separately and are
 outlined in Table VIII E[i) 
and Fiq. VIII E[i] respectively.
 There was no significant 
difference between the clinical 
and haemodynamic features of 
the 2 qroups. 
Table VIII E[i]: 
Number 
Comparative features 




Age at presentation (years) 32.0
 





NSS = Not statistically significa
nt. 
of PPH and TPH 
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Fifty-four per cent of the PPH group survived
 40 months from 
the onset of symptoms. The significanc
e of this finding is 
weakened by the fact that, because of inadeq
uate information, 
10 patients could not be included in 
the analysis of 
survival. This could be construed as showin
g that all 10 had 
died without our being informed. Although
 this may be true 
of two patients who had severe pulmonary hyp
ertension it does 
not necessarily apply to the remaining 8 
all of whom had 
only moderate pulmonary hypertension. One is
 still attending 
our clinic 36 months after the onset o
f symptoms, is 
clinically stable and is highly likely to su
rvive well beyond 
40 months; three residents of neighbouring 
southern African 
countries were seen shortly before a period 
of intense socio-
political upheaval in those countries and ma
y have emigrated 
or moved as part of the immense changes th
ose communities 
underwent. The doctors attending two of thes
e cases wrote to 
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notify us of improvement of clinical and in one 
case 
electrocardiographic features one and two years after b
eing 
seen respectively. Each of these 8 patients was living as 
part 
of a family who could have replied to our letter of enq
uiry 
had they still been resident at their original address. 
Two of our patients showed improvement in .sym~oms 
and 
clinical features. Effort tolerance improved from NYHA g
rade 
3 to grade 1, and right ventricular 3rd and 4th heart so
unds 
disappeared over a follow up period of 10 years in the 
case 
of the first patient. The second patient (with SLE) show
ed a 
less dramatic improvement in effort tolerance 
with 
disappearance of ' right ventricular 4th sound and mode
rate 
improvement in measured maximal power output over a period
 of 
3 years. Repeat cardiac catheterization has not 
been 
performed as the attending physician felt that ~he sl
ight 
associated risk was not warranted in the first patient 
and 
the second patient is _satisfied with her present condit
ion. 
Two other patients, both on long term vasodilator thera
py, 
appear to have stabilised. Their symptoms and physical s
igns 
have remained unchanged over 4 and 8 years follow
 up 
respectively. One of these patients, who has PPH associ
ated 
with chronic active hepatitis, showed a slight reduction 
in 
measured maximal power output over the first 2 years
 of 
follow up (700 to 600 kpm/min) but showed no fur
ther 
deterioration when tested 2 years later. The second pati
ent, 




performed far better 8 years later 
achieving a maximal power output of 
500 kpm/min (60% 
predicted maximum) with 
a normal blood pressure response. 
Although we have classified her as having 
remained stable on 
the basis of our clinical assessment, the
 improved exercise 
test result may reflect 
true improvement. Repeat 
catheterization has not been performed. 
Walcott and his colleagues reported a 44% 
three year survival 
with only 3 of their 23 cases surviving fo
r longer than 10 
years.( 123 ) Fuster et al reported a m
edian survival from 
diagnosis to death of 1.9 years (range 
0 to 16 years) in 
their 112 patients. More than three-qua
rters of the deaths 
in their study occurred within 5 years of 
diagnosis(
39 >. The 
condition was thus thought to have a rath
er dismal prognosis 
but this view has had to be revised in the l
ight of a recent 
report by Rozkovec et al that 12 of t
heir 34 patients 
survived longer than 5 years and that 
evidence of regression of the disease(
99 >. 
4 patients showed 
Although a greater proportion of our TPH 
group than our PPH 
group survived 40 months, the dif
ference was not 
statistically siqnificant. 
VIII E(ii): PPH associated with connective
 tissue disease: 
Six of the PPH patients had an associated
 connective tissue 
disease: two had the CREST variant of sy
stemic sclerosis, 
three had SLE and one had juvenile chron
ic arthritis. The 
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characteristics and survival curves o
f the PPH patients with 
and without an associated 
connective tissue disease were 
analysed separately and are outlined 
in Table VIII E[ii] and 
Fiqure VIII E[ii] respectively. 
Table VIII E[ii]: Comparative features
 of PPH patients with 
and without an associated connec
tive 
tissue disease: 







Aqe at presentation (years) 31.0 3
7.3 NSS 
Number (%) who had 
catheterization 20(91%) 
3(50%) NSS 
PAP (mmHq) 71.2 4
5.0 <0.05 
NSS = Not statistically sianificant. 
Fi q VI I I E [ i i ] : Survival to 40 months of 
PPH patients with 
and without associated connective tissu
e disease. 
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Despite significantly less severe pulmonary hyper
tension at 
the time of initial assessment, the qroup with an 
associated 
connective tissue disease had a lower 40 
month survival. 
However, as the qroup was rela
tively small this difference 
did not reach statistical siqnificance. 
noted by Rozkovec and his colleagues: 
A similar trend was 
the mean survival of 
their PPH patients with an associated connecti
ve tissue 
disease was 3.4 years while that of the whole grou
p was 7.3 
years. However, as the number of pa
tients with associated 
connective tissue diseases in their series was also
 
relatively low, this difference was not significan
t( 99 ). A 
study including a larger number of patients with P
PH with an 
associated connective tissue disease is needed
 to show 
whether the proqnosis of such patients is indeed w
orse than 
other PPH patients. 
VIII E(iii): Effect of Iona term anticoaaulant the
rapy on 
survival. 
El even patients received long term anticoagulan
t therapy. 
There was no significant difference between th
e initial 
clinical and haemodynamic characteristics of the p
atients who 
were treated with chronic anticoagulation and tho
se who were 
not (Table VIII E[iii]). 
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Table VIII E[iii]: Comparative feat
ures of patients who 
receivea long term oral anticoagu
lant 
therapy and those who did not. 
Number 
Age at presentation (years) 




















Fi g VI I I E [ i i i ] : Survival to 40 months of
 PPH patients 
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The trend towards improved survival 
shown by the patients on 
anticoagulant 
siqnificance. 
therapy did not attain statistical 
Fuster and his colleagues showed a sm
all but 
siqnificant improvement in survival




VIII E(iv): Long term vasodilator therap
y. 
Long term vasodilator therapy was attem
pted in . 6 patients 
using agents to which the patient had re
sponded favourably 
during testing. The treatment
 was withdrawn from 3 patients 
because of severe side effects. 
Isosorbide dinitrate, 
hydrallazine and nifedipine all caused se
vere headaches. In 
1 patient the introduction of diazox
ide was reputedly 
associated with the development of perip
heral oedema and it 
was thus discontinued by the doctor attend
ing her. 
A fourth patient who died while 
still on sublingual 
isoprenaline underwent a repeat c
atheterization shortly 
before her death. This showed that
 the PAP had risen 
significantly since the original s
tudy three months 
previously (from 77 to 90 mmHg). Two p
atients are still on 
vasodilator therapy after 37 and 96 month
s respectively. The 
first patient (who is on isosorbide dinit
rate) showed no 
significant change in PVR when recatheteri
zed 13 months after 
the initial study. The second patient w
ho is on isosorbide 
dinitrate, verapamil and a thiazide diu
retic has · not been 
recatheterized. A reversible deteriorat
ion of her effort 
tolerance corresponding with a period o
f withdrawal of her 
medication suggests that the therapy is e
xerting a beneficial 
effect. 
Pearl and his coworkers reported long te
rm improvement in 
symptoms in 5 of 6 patients treated 
with long acting 
nitrates(SG). Other authors have noted 
the persistence of a 
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beneficial effect on the PVR an
d CI after 3 to 8 months of 
1 
. (67, 102) N'f d' . h b 
therapy with oral hydral az1ne 
1 e 1p1ne as een 
shown to effect an improvement 
in pulmonary haemodynamics 
h 
(12,27,101) h'l 
which persisted after 14 months 
oft erapy w 1 e 
isoprenaline has had a similar 
effect up to 47 months in 
' bl t. t ( 
85 ' 88 ) T f . t. t 
r h 
su1ta e pa 1en s • wo 
groups o 1nves 1ga o s ave 
shown that diazoxide continues to
 exert a beneficial effect 




on the pulmonary vascu ature a te
r 
continuous infusion of prostacycl
ine for 13 months achieved a 
. ( 45) 
satisfactory result in one patien
t • 
The most common response to vasod
ilator therapy in general is 
a decrease in PVR and an increas
e in CO with ' no significant 
change in PAP. The reduction i
n PVR achieved by some agents 
is thought to be secondary to 
an increase in co(
125 ). 
However, studies in dogs have show
n that isosorbide dinitrate 
decreased PVR when CO was maint
ained constant by bypassing 
either the right or the left vent
ricle(
89 ). 
Hermiller et al reported that iso
sorbide dinitrate was the 
only one of 6 vasodilators teste
d to achieve a significant 
reduction in PAP(
44 ). Our study confirmed that isosorb
ide 
tended to be more effective in
 reducing pulmonary artery 
pressure than the other agents ev
aluated. 
However, merely decreasing PVR with
out reducing PAP may be 
beneficial to the patient. Several
 studies have shown an 
inverse relationship between PVR
 and survival with the PAP 
itself having little effect on p
rognosis(
39 , 93 , 99 ). Rubin 
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and his colleagues reported that nifedipine 
increased right 
ventricular ejection fraction and reduced
 end diastolic 
volume measured by radionuclide angiocardio
graphy when PVR 
was significantly reduced although pulmonary 
artery pressures 
(101) 
r emained relatively unchanged • In add
ition there is 
often an improvement in symptoms associated w
ith the increase 
. . (12,67,101) 
in cardiac output achieved by vasodilator the
rapy • 
In general, our experience with vasodilator
 therapy in the 
management of PPH has been less encouraging t
han some reports 
by other authors(
12 ' 67 ' 1
02 ' 125 ). A similar lack of 
significant effect 
colleagues(
44 >, and 
therapy on overall 
was shown by Hermiller • 
a beneficial effect of 
and his 
vasodilator 
mortality has not as yet 
h 
(39,93) 
sown • Reliable assessment of both
 short and 
been 
long 
term effects of vasodilator therapy is co
mplicated by a 
marked spontaneous variability in PVR from h
our to hour in 
th 
. (94) 
ese patients and by occasional spontaneous
 regression 
of the condition(
99 >. In spite of this, there is sufficient 
ev idence to show that there is indeed a sub
group of these 
patients in which long term vasodilator thera
py is effective 
in achieving symptomatic and haemodynamic imp
rovement. 
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VIII E(v): Heart-lung transplantation. 
Only one patient underwent heart-lung transplanta
tion during 
the period of this study. 
performed post-operatively, 
No haemodynamic studies were 
but she was symptomatically 
improved. The subsequent developme
nt of chronic rejection 
and persistent pulmonary tuberculosis necessita
ted repeat 
transplantation one year later. 
After performing 28 heart-lung transplants during
 the course 
of 4
1 /2 years the Stanford group point out that because
 of 
the uncertainties associated with this form of 
therapy at 
present it should not yet be undertaken as a routi
ne clinical 
(10) . 
procedure • They attempt to select patients
 who have 
limiting symptoms and who are expected to live o
nly one or 
two years more without surgery. Actuarial survi
val curves 
based on their data predict 1 and 2 year survial r
ates of 71% 
and 57% respectively(
25 ). Previous authors have attempted to 
define criteria to enable identification of the P
PH patient 
wi th a poor prognosis who would be a suitable can
didate for 
heart-lung transplantation(
39 , 93 , 99 ). We have attempted to 
identify features associated with short and 
long term 
survival in our patient group. Our findings are e
xpressed in 
the next section. 
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VIII F: Features of short and long t
erm survivors. 
Seven patients with full haemodynamic
 evaluation and complete 
follow up died within 12 months of in
itial catheterization. 
These constituted the short survival 
group. A similar number 
who survived 40 months or longer f
rom initial evaluation 
constituted the long survival group
. 
clinical features of the 2 gro
ups 






Table VIII F[i]: Demograph
ic and historical features of 
short and lona survival qroups. 
Number 
Age {years) 















{% of females) 
Number of pregnancies 
Oral contraception 















































There was no significant difference between the age of onset 
of the disease in the 2 groups. This 
lack of correlation 
bet ween age of onset and prognosis has been noted in previous 
t d
. (39,99) 
s u ies • As paediatric patien
ts are not seen at our 
c li nic our study group did not include children. 
However, 
the 3 patients under the age of 15 years who were included 
al l died within 3 years of the onset of symptoms. Fuster and 
his colleagues found that 64% of their patients who were 14 
year old or younger died during the first year of follow 
This led them to postulate that younger patients 
wi t h PPH do badly, but as their group of younger patients was 
re l atively small this apparent difference in survival was not 
statistically significant. 
Se x was not a factor influencing prognosis. Fuster and his 
c pworkers noted the same finding(
39
> whereas Rich and Levy 
n oted a larger proportion 
survivors( 93 >. One of our 
of females among their non 
patients fell pregnant but this 
d i d not have any adverse effect on her clinical or
 
haemodynamic status. This observation is in conflict with a
 
p r evious report that pregnancy worsens the prognosis of 
p a t ients with PPH. The mean survival after pregnancy was 
r eported to be less than 5 years<
69 >. However, this 
assertion was challenged by the finding of Rozkovec et al. 
that preqnancy at the time of diagnosis seemed to be a 
favourable prognostic factor (
99 >. All five of their cases 
who presented in late pregnancy or after delivery had 
prolonged survival. Spontaneous improvement occurred in 2. 
They postulated that the stress of pregnancy might have 
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induced the onset of symptoms at an ear
lier stage of the 
disease process and that there might have
 been an element of 
pregnancy 
delivery. 
induced vasoconstriction which reversed
· after 
A significantly larger proportion of fem
ales in 
our lonq survival group had been pregnant 
at various periods 
prior to the onset of this conditio
n. The rate of 
progression of the condition may slow whe
n these pregnancy 
related hormonal stimuli are removed re
sulting in a better 
prognosis than other forms of PPH in 
which non-hormonal 
factors may play a more significant causat
ive role. 
There was no significant difference betwee
n other demographic 
features and the nature and duration of s
ymptoms of the two 
groups. 
Table VIII F[ii]a: 
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Clinical, chest radiographic and 
electrocard i ographic features of the 
short and long survival groups. 
Cl in ical signs: 
Elevated JVP 
Mean JVP 








Right ventricular heave 100% 




















Ri ght ventricular 
strain 
Right axis deviation 
Right atrial enlarge-
ment 
Right bundle branch 
block 









































The clinical and chest radiographic feature
s of the two 
groups were not significantly different. 
All of the patients in our short surviv
al group had 
electrocardiographic evidence of right
 ventricular 
hypertrophy. This feature occurred signifi
cantly less 
frequently in the long survival group. 
Table VIII F[ii]b: Comparison of clinical, che
st radiographic 
and electrocardiographic features of short 
and long survival groups in this study9
~?d 
that of Rozkovec, Montanes and Oakley 
(% of patients). 
Feature Study Short Long 
II p 11 
survival survival 
Clinical features Chapman NS 
Rozkovec NS 
ECG 
-Right ventricular Chapman 100 43 <0.05 
hypertrophy Rozkovec 100 83 NS 
Right axis Chapman 100 86 NS 
deviation Rozkovec 100 66.6 <0. 05 
Right atrial Chapman 50 14 NS 
enlargement Rozkovec 94.4 25 <0.0005 
Chest X-Ray 
Right ventricular Chapman 86 57 NS 
enlargement Rozkovec 100 66.6 <0.01 
Apart from a higher prevalence of radiographi
cally apparent 
right ventricular enlargement in their short s
urvival group, 
the findings of the Hammersmith group in this 
regard were 
similar to our own (Table VIII F[ii]b). 
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Although features of right ventr
icular hypertrophy were also 
noted in all patients in the
 short survival group in the 
1 
( 99) 
study by Rozkovec et a , 
this was not significantly 
different from the prevalence 
of this feature in the groups 
with a longer survival. Rig
ht axis deviation and right 
ventricular strain pattern o
ccurred significantly more 
frequently in their short surviv
al group. The prevalence of 
these features in our short surv
ival group although somewhat 
higher than in the long surviva
l group was not significantly 
so. 
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Table VIII F[iii]a: Pulmonary angiographic
 and haemodynamic 






(< 12 mths) 
Proximal dilatation 66% 
Main or several lobar 
pulmonary artery defects 0% 
Small vessel occlusion 67% 
Haemodynamic parameters 











PAP = Mean pulmonary artery pressure 
PVR = Pulmonary vascular resistance 
SVR = Systemic vascular resistance 
CI = Cardiac index 















There was no significant difference between
 the pulmonary 
angiographic features of the short and long s
urvival groups. 
The PAP and PVR were significantly higher
 in the short 
survival group. Other authors have failed to show 
a 
significant relationship between survival an
d the degree of 
pulmonary hypertension although their longer surviving 
patients tended to have slightly lower p
ulmonary artery 
pressures (Table VIII F[iii]b). These author
s have noted a 
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significantly hiqher PVR in their short survival g
roups. 
Fuster and his colleagues found systemic arterial 
oxygen 
saturation to be a good 
predictor of survival 
(p<9J.00001) <
39 >. 
Table VIII F[iii]b: Comparison of haemodynamic parame
ters of 
short and lonq survival groups in this 
study and(g~?se of Rozkovec, ~~~fanes 
and Oakley and Rich and Levy • 
Parameter Study Short 
Long "p" 
survival survival 
PAP, mmHg Chapman 84 61 
<0.05 
Rozkovec 64 61 NS 
( i vs ii) 
Rich & Levy 74 53 NS 
PVR, units Chapman 32 13 
<0.05 
Rozkovec 21 12 <0.005 
{i vs iii) 
Rich & Levy 57 20 <0.911 
SVR , units Chapman 27 21 N
S 
Rozkovec 28 19 (0.01 
Rich & Levy 64 43 <0.915 
CI, lmin-lrn-
2 Chapman 2.1 2.7 NS 
Rich & Levy 1.2 2.3 <0.01 
RAP, mrnHg Chapman 9 9 N
S 
Rich & Levy 17 6 <0.tH 
Both previous studies noted a significantly lower
 mean 
cardiac index in their short survival group but the 
trend 
towards a lower mean cardiac index in our short su
rvival 
group did not attain statistical significance. Mea
n right 
a t rial pressure was significantly higher in Rich and 
Levy's 
short survival group {17 vs 6 mmHg; p<0.0l). H
owever, 
neither we nor Rozkovec and his colleagues noted
 any 
significant difference between the two groups with resp
ect to 
t his parameter. Although no significant difference in
 SVR 
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existed between the two groups in our study, both Rich and 
Levy and the Hammersmith qroup reported a significantly 
higher mean SVR in their short survival group. 
Rozkovec and his colleagues noted that a patent foramen ovale 
was associated with a longer survival and postulated that 
such a shunt permitted adequate left ventricular filling at 
times of increased demand and prevented sudden death<
99
). 
Only one of our patients had a patent foramen ovale. It did 
not appear to confer any protective benefit on her as she 
died within 15 months of the onset of symptoms. 
We were unable to compare the responsiveness to vasodilators 
in the 2 groups as too few of these patients with adequate 
follow up were tested to enable any meaningful conclusions to 
be drawn. However, Rich and Levy noted no difference in the 
acute response to vasodilator therapy between the short and 
long survival groups<
93 ). 
Various authors have sought to define criteria to enable 
prediction of survival of the individual patient. Such 
criteria would be of enormous assistance to the attending 
physician in evaluating the advisability and timing of such 
aggressive therapeutic options as heart-lung transplantation. 
Analysis of the haemodynamic parameters measured at diagnosis 
in the short and long survival groups in relation to survival 
time from presentation by means of Spearman's rank 
correlation failed to show a relationship. This was limited 
by the fact that not all haemodynamic data was present for 
all patients. 
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Rich and Levy found that the stroke volume 
index was the best single predictor of survival, with a 
figure of less than 17 ml/beat/m
2 associated with a poor 
prognosis. Only one of our short survival group had a stroke 
volume index calculated. The figure of 20 ml/beat/m
2 
in this 
patient does not entirely support the findings of Rich and 
Levy, but it was certainly considerably lower than the mean 
of 43 
2 
ml/beat/m in the long survival group. Right atrial
 
pressure was the best measured predictor of survival in their 
study, with a right atrial pressure of greater than 10mmHg 
also predictive of a poor prognosis. The mean right atrial 
pressure in our two groups, however, was similar. They found 
cardiac index, pulmonary vascular resistance and pulmonary 
artery pressure 
prognosis< 93 ). 
to be relatively poor predictors of 
Rozkovec and his colleagues noted that cardiac output was 
directly related to survival and that there was an inverse 
relationship between duration of survival and PVR, SVR and 
left ventricular end diastolic pressure. Systemic and 
pulmonary arterial and right atrial pressure did not 
correlate with survia1<
99 ). 
Un i variate analysis of various haemodynamic variables by 
Fuster et al revealed that pulmonary and systemic arterial 
oxygen saturation and total pulmonary resistance were the 
most strongly predictive of early death. The 3 year survival 
was 55% among patients whose pulmonary arterial oxygen 
saturation was 63% or higher while it was 17% in those in 
whom it was lower(
39 ). 
Page 87 
Stepwise multivariate analysis 
identified that pulmonary arterial oxygen saturation
 and 
anticoagulant therapy were the only two v
ariables of 
prognostic significance. We did not me
asure pulmonary 
arterial oxygen saturation but found a significant differ
ence 
in systemic arterial oxygen saturation between our short 
and 
long survival groups. 
There are as yet still no adequate criteria by 
which 
individual patients can be categorized prospectively
 into 
specific prognostic groups at the time of initial evalua
tion • 
. 
Our study is the first to show a significantly higher 
mean 
pulmonary artery pressure in a short survival group. 
No 
patient with a mean pulmonary artery pressure of 75 mm
Hq or 
greater survived for longer than 12 months. 
Paqe R8 
IX: CONCLUSION 
This study has analyse
d the features and proa
ress of 38 
patients with PPH over a 
perion of 28 years at G
roote Schuur 
Hospital. 
The first aim of the 
study was to analyse th
e clinical 
features of these pati
ents and to compare them
 with the 
features of a group of
 patients with TPH. 
The qreater 
prevalence of Raynaud's p
henomenon in the PPH qro
up confirms 
previous reports(
1221123 ) and suqqests the exis
tence of a 
common mechanism causing
 spasm of both the pul
monary and 
digital arterioles(
35 ). The PPH qroup was yo
unqer and had a 
right ventricular fourth
 heart sound detec
ted more 
frequently. A similar pr
oportion of the females i
n the two 
aroups had previously be
en pregnant but each mo
ther in the 
TPH qroup had delivered s
iqnificantly more childre
n. While 
the association of pulmo
nary thromboembolism wit
h pregnancy 
is well recoqnised(lR), 
certain authors have pos
tulated that 
pregnancy or the adminis
tration of female hormone
s also plays 
a role in the pathoqenes
is of primary pulmonary h
ypertension. 
The clinical features of
 the two qroups were sim
ilar apart 
from the absence of a clin
ically detectable fourth
 heart 
sound and a higher preval
ence of lower extremity 
varicosities 
in the TPH aroup. The PPH
 qroup had a sianificantl
y hiaher 
prevalence of electroca
rdioqraphic evidence of 
right axis 




re similar in both aroups
. 
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Although all patients with total lung capacit
y below two-
thirds predicted were excluded in an attempt 
to eliminate 
restrictive lung disease contributing to th
e pulmonary 
hypertension, the mean value of this parameter 
in this study 
was · well below predicted and significantly low
er than that 
found in the TPH group. 
previously. ( 9 , 47 , 107 ) 
Similar findings have been reported 
The physiological mechanism 
responsible for the restrictive ventilatory pat
tern has not 
yet been defined. Clarification of the frequ
ency with which 
this occurs awaits a study in which interstitial
 lung disease 
is histologically excluded in all patients i
n the study 
group. 
As none of the PPH patients who were subjected t
o lower limb 
venography showed a positive result whereas ove
r half of the 
patients- in the TPH group had evidence of 
thrombus, a 
positive venogram in this cli~ical setting ap
pears to be 
fairly strong evidence in favour of a diagnosis 
of TPH. 
Pulmonary artery pressure was significantly high
er in the PPH 
group. A similar trend noted by D'Alonzo and his 
colleagues 
did not attain statistical significance. (
23 ) The role of 
pulmonary angiography or open lung biopsy in d
istinguishing 
these two entities is controversial. (
79 ) Surgery and 
pulmonary angiography have been reported to hav
e a greatly 




Other authors have 
pulmonary 
reported no 
increased risk associated with open lung bio
psy in such 
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patients. (li) We do not routinely perform open lung biopsy 
and prefer to use pulmonary angiography to clarify the 
diagnosis. No untoward effects of pulmonary angiography were 
noted during this study. The recent introduction of non-
ionic contrast medium is expected to reduce the risk 
associated with pulmonary angiography even further. 
Radionuclide lung scanning proved a safe and effective non-
invasive means of distinguishing between these two 
conditions. 
The second aim of the study was to evaluate the prognosis of 
these patients. Fifty-four percent of the PPH group survived 
40 months or more from onset of symptoms. As the TPH group 
was relatively small, the trend towards a better survival at 
40 months than in the PPH group was not statistically 
significant. Within the PPH group a trend towards a worse 
prognosis in patients with associated connective tissue 
disease did not attain statistical significance. Although 
repeat haemodynamic studies have not been performed, it 
appears clinically that in 2 PPH patients the disease 
progression has halted while 2 further patients have shown an 
improvement of symptoms and exercise tolerance suggestive of 
regression of the disease. 
The third aim of the study was to assess the efficacy of 
various therapeutic strategies in the PPH patients. The 
trend towards a better 40 month survival in patients on long 
term oral anticoagulants did not reach statistical 
significance. We were unable to identify a group of patients 
Page 91 
who consistently responded to the various 
vasodilators 
tes t ed: different agents showed 
different degrees of 
I 
effectiveness in different patients. 
Severe side effects 
prompting cessation of long term vasodilator thera
py occurred 
in 3 of the 6 cases in whom it was attempted. 
A beneficial 
effect appears to have occurred in two patient
s. There 
appears to be a small group of patients in whom s
uch therapy 
is effective. One patient 
underwent heart-lung 
transplantation. Twelve months later she was stil
l alive but 
had undergone repeat transplantation because 
of chronic 
rejection. Actuarial survival curves pred
ict one and two 
year survival rates after heart-lung transplantat
ion of 71% 
and 51% respectively<
25 >. Only those patients with a severe 
progressive form of the disease should be cons
idered for 
surgery. 
The fourth aim of the study was to identif
y factors 
predictive of the outcome of PPH. Neither clinica
l nor chest 






hypertrophy was significantly more common, w
hile mean 
pulmonary artery pressure and pulmonary vascular 
resistance 
were higher in the short survival group. Howev
er the wide 
range of values within both groups of the paramete
rs measured 
makes accurate prediction of survival for the 
individual 
patient extremely difficult. No correlation w
as found 
between initial haemodynamic parameters measured a
t diagnosis 
and survival in the short and long survival
 groups 
Previously proposed criteria for prediction<
93 > have not been 
confirmed by other studies<
99 >. 
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The assessment of the 
prognosis of an individual patient requ
ires careful 
cor relation of all clinical and haemodynamic data gathere
d at 
the time of diaqnosis with assessment of the rate
 of 
progression by means of regular clinical re-evaluation. 
The 
recently developed technique of non-invasive assessmen
t of 
pulmonary artery pressure(
2l) promises to be of value in 
following these patients and assessing the stage of 
the 
disease at which heart-lung transplantation offers a be
tter 
prognosis than conservative treatment. 
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